Business
Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio
CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical
About this update from Onconetix, Inc.
[{"type":"text","content":"CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today announced plans to establish a medical sales representative team with IQVIA to market Blue Water’s commercial portfolio. This portfolio is highlighted by ENTADFI®, a treatment for benign prostatic hyperplasia, and ZONTIVITY®, a medication for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. In this collaboration, IQVIA and Blue Water will jointly work to build a sales team for Blue Water’s commercial products, covering key geographies that account for a large percentage of prescriptions in target markets, including urology and cardiology. Blue Water and IQVIA have agreed to commence certain activities on a provisional basis and are working towards finalizing a definitive agreement. Upon execution of a definitive agreement, Blue Water expects that IQVIA representatives and Blue Water’s commercial team will seek to identify high-volume prescribers in key markets to maximize uptake and socialization of Blue Water products. IQVIA, a global provider of data analytics and solutions for the development of robust medical sales representative teams to support emerging life science companies, has a proven track record of establishing effective medical sales teams. “This collaboration with IQVIA is a promising step towards the launch of ENTADFI® and the six assets we are acquiring,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. “With decades of experience helping companies commercialize and market their products, we are thrilled to collaborate with IQVIA to build out our sales team and educate providers on the benefits of our products to get patients access to therapies they need.” In addition to the purchase of ENTADFI® in April 2023, Blue Water recently signed an Asset Purchase Agreement on June 13, 2023 for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. Blue Water management intends to work closely with IQVIA to develop a strategy to market Blue Water’s portfolio of assets to physicians across the United States. About Blue Water Biotech Blue Water B...